Leerink Partnrs Estimates Shattuck Labs FY2024 Earnings

Shattuck Labs, Inc. (NASDAQ:STTK) – Research analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Shattuck Labs in a research report issued on Monday, March 17th. Leerink Partnrs analyst F. Khurshid anticipates that the company will post earnings of ($1.42) per share for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Shattuck Labs’ current full-year earnings is ($1.48) per share. Leerink Partnrs also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.93) EPS and FY2026 earnings at ($0.93) EPS.

Separately, Leerink Partners started coverage on shares of Shattuck Labs in a research report on Monday, March 17th. They issued an “outperform” rating and a $4.00 target price for the company. Four equities research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Shattuck Labs Stock Performance

STTK opened at $1.20 on Thursday. The company has a 50-day moving average of $1.24 and a 200-day moving average of $1.58. The company has a market capitalization of $57.29 million, a P/E ratio of -0.78 and a beta of 1.66. Shattuck Labs has a 1-year low of $0.94 and a 1-year high of $11.76.

Institutional Investors Weigh In On Shattuck Labs

Institutional investors have recently modified their holdings of the business. Zacks Investment Management bought a new stake in shares of Shattuck Labs during the 4th quarter valued at about $25,000. Virtu Financial LLC bought a new stake in shares of Shattuck Labs during the 4th quarter valued at about $30,000. Atom Investors LP bought a new stake in shares of Shattuck Labs during the 3rd quarter valued at about $35,000. Readystate Asset Management LP bought a new stake in shares of Shattuck Labs during the 3rd quarter valued at about $39,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Shattuck Labs during the 4th quarter valued at about $45,000. Institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.